跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 30,141 条关于
“ALK-positive NSCLC”
全部
30,141
临床试验
18,697
药物
621
机构
86
资讯
10,737
去年
ALNEO Trial Demonstrates Promising Perioperative Alectinib Activity in Stage III ALK-Positive NSCLC
去年
Alectinib Plus Bevacizumab Shows Promising Results in First-Line Treatment of ALK-Positive NSCLC
去年
Adjuvant Crizotinib Fails to Improve Disease-Free Survival in Early-Stage ALK-Positive NSCLC
去年
Lorlatinib Shows Impressive 5-Year PFS Results in ALK-Positive Advanced NSCLC
5个月前
Xuanzhu Biopharma's DiLuoAke Demonstrates Superior Efficacy Over Crizotinib in Phase III ALK-Positive NSCLC Trial
4个月前
Xcovery Partners with EVERSANA to Expand Commercial Launch of ALK-Positive NSCLC Drug Ensacove
去年
Ongoing Trials Explore Novel Combinations and Adjuvant Therapies in EGFR- and ALK-Mutant NSCLC
去年
Adjuvant Alectinib Confirmed as New Standard of Care in ALK+ NSCLC with Favorable Safety Profile
去年
Ensartinib Approved by FDA for First-Line ALK-Positive Non-Small Cell Lung Cancer
去年
Nuvalent Fast-Tracks First Approval for Zidesamtinib in ROS1-Positive NSCLC by 2026
第 1 页,共 1074 页
上一页
下一页